Home

Poster - Monitoring cognitively-impaired subjects in an interactive Internet-based clinical trial of a multi-factorial treatment based on a molecular model of chronic disease

Type: Abstract presentation
Presented by: Meg Mangin RN
Conference: Days of Molecular Medicine 2008
Location: Karolinska Institue, Sweden
Date: April 17 -19, 2008
Related content: poster; Notes from the Conference by Amy Proal
Notes: Meg Mangin's presentation begins at 16:50.

Abstract

Based on this author’s experience on an NIH monitoring board, we devised and conducted a phase II clinical study of a VDRThe Vitamin D Receptor. A nuclear receptor located throughout the body that plays a key role in the innate immune response.-agonist, antibacterial therapy which demonstrated proof of concept of a novel biological description of the autoimmune disease process1). We collected evidence that restoring innate immune system competence will reverse the disease progression2). This multi-factorial therapy activates the Vitamin D Nuclear-Receptor, enabling the innate immune system to attack the intracellular microbiotaThe bacterial community which causes chronic diseases - one which almost certainly includes multiple species and bacterial forms. which dysregulates Vitamin D metabolism. Additionally, it reduces elevated 1,25-dihydroxyvitamin-D and reduces co-morbid cognitive impairment3). Nurses who monitor the subject’s progress are well-grounded in molecular science to help them accurately assess the effects of the recovery process. Instruction of subjects and their participating physicians occurs online. All communication is done in writing using a standard report form to facilitate accurate assessment and collect objective data. Ongoing, regular reports and rapid feedback by Nurses, ensures early detection of unexpected treatment effects. We describe the observational skills needed, the assessment techniques used and the limits/advantages of monitoring subjects using this format. As a result of the therapy subjects experienced diminishing relapse and remission of inflammatory symptoms4). Over 3-5 years this resulted in recovery from the disease process.

References

1)
Vitamin D discovery outpaces FDA decision making.
Marshall TG
Bioessays30p173-82(2008 Feb)
2)
Marshall TG et al. The Journal of the Interregional Clinical-Diagnostic Center, Kazan. ISSN:1726-6149
3)
Mangin M. Abstract presentation Days of Molecular Medicine April 2008
4)
Sarcoidosis succumbs to antibiotics--implications for autoimmune disease.
Marshall TG, Marshall FE
Autoimmun Rev3p295-300(2004 Jun)
home/publications/mangin_days_of_molecular_medicine_2008.txt · Last modified: 01.03.2012 (external edit)
© 2015, Autoimmunity Research Foundation. All Rights Reserved.